Peritoneal mesometrial resection with lymphadenectomy following prior hysterectomy in intermediate/high-risk endometrial cancer: feasibility and safety

Author:

Buderath PaulORCID,Elgharib MohamedORCID,Kimmig RainerORCID

Abstract

Abstract Objective Peritoneal mesometrial resection (PMMR) plus targeted compartmental lymphadenectomy (TCL) aims at removal of the locoregional cancer field in endometrial cancer (EC). Optimal locoregional control without adjuvant radiotherapy should be achieved concomitantly sparing systematic lymphadenectomy (LNE) for most of the patients. However, intermediate/high-risk EC is often definitely diagnosed postoperatively in simple hysterectomy specimen. Our aim was to evaluate feasibility and safety of a completing PMMR + TCL in patients following prior hysterectomy. Methods We evaluated data from 32 patients with intermediate/high-risk EC treated with PMMR + TCL or systematic pelvic and periaortic LNE following prior hysterectomy. Perioperative data on disease characteristics and morbidity were collected and patients were contacted for follow-up to determine the recurrence and survival status. Results We report data from 32 patients with a mean follow-up of 31.7 months. The recurrence rate was 12.5% (4/32) without any isolated locoregional recurrences. Only 21.9% of patients received adjuvant radiotherapy. Rates of intra- and postoperative complications were 6.3% and 18.8%, respectively. Conclusion Our data suggest that robotic PMMR can be performed following prior hysterectomy when previously unknown risk factors arise, albeit with a moderate increase in morbidity. Moreover, despite a relevant reduction of adjuvant radiotherapy, follow-up data suggest an excellent locoregional control even without adjuvant radiotherapy.

Funder

Universitätsklinikum Essen

Publisher

Springer Science and Business Media LLC

Subject

Obstetrics and Gynecology,General Medicine

Reference33 articles.

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403

2. Robert Koch-InstitutGdeKiDeVH (2021) Krebs in Deutschland für 2017/2018. Robert Koch-Institut, Berlin

3. Lim MC, Won YJ, Ko MJ, Kim M, Shim SH, Suh DH et al (2019) Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015. J Gynecol Oncol 30:e38

4. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzi- nom, Kurzversion 1.0, 2018, AWMF Registernummer: 032/034-OL. 2018. http://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/. Accessed 19 Nov 2018

5. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Endometriumkarzinom, Langversion 2.0, 2022, AWMF- Registernummer: 032/034-OL. c2022. https://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/. Accessed 14 Jun 2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3